Business Context and Reporting Period
This Form 8-K is filed by Onconova Therapeutics, Inc. (not Traws Pharma, Inc.) for the reporting period of November 22, 2019. The company is a Delaware corporation with securities traded on The Nasdaq Capital Market under the symbols ONTX and ONTXW.
Key Financial Metrics
The filing does not provide specific values for revenue, profit, cash flow, margins, or debt. The document focuses on a regulatory compliance issue regarding the Nasdaq Capital Market's minimum stockholders' equity requirement of $2.5 million, which the company failed to meet by November 18, 2019.
Material Changes and Events
- Delisting Notice: Nasdaq Staff advised the company that it intends to delist its securities due to non-compliance with the $2.5 million stockholders' equity requirement.
- Hearing Request: The company intends to request a hearing before the Nasdaq Hearings Panel on November 26, 2019, to seek an additional 180-day extension to regain compliance.
- Public Offering Dispute: On November 22, 2019, Nasdaq Staff verbally advised that a public offering announced on November 21, 2019, does not qualify as a "public offering" under Rule 5635(d) of the Nasdaq Listing Rules. The company disputes this interpretation and intends to proceed with the closing of the offering.
Outlook, Risks, and Management Commentary
Management acknowledges that while the public offering is a meaningful step toward compliance, it is not expected to enable the company to regain compliance on its own. The company is preparing a comprehensive plan of compliance for the stockholders' equity deficiency to be reviewed by the Panel. There is no assurance that the Panel will accept the plan or that the company will maintain its Nasdaq listing.
Investor Verification Checklist
- Verify the outcome of the hearing request scheduled for November 26, 2019, regarding the 180-day extension.
- Confirm whether the Nasdaq Staff issues a formal written notice regarding the non-compliance with Rule 5635(d) concerning the public offering.
- Monitor the closing status of the Form S-1 public offering and its actual impact on stockholders' equity.
- Review the final plan of compliance submitted to the Nasdaq Hearings Panel.